<i>PPARG</i> Negatively Modulates <i>Six2</i> in Tumor Formation of Clear Cell Renal Cell Carcinoma

Wu, Yafei; Song, Tao; Liu, Ming‐Wei; He, Qi; Chen, Lei; Liu, Yamin; Ni, Dongsheng; Liu, Jianing; Hu, Yanxia; Gu, Yue; Li, Qianyin; Zhou, Qin; Xie, Yajun

doi:10.1089/dna.2018.4549

Cited by 14 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TZD18, a dual PPARγ/α ligand, reduced the growth and increased the apoptosis of human gastric cancer cells by increasing the expression of BAX and p27kip1 and decreasing Bcl-2 (Ma et al, 2019). Similar activity was observed for renal carcinoma cells (Wu et al, 2019), cutaneous squamous cell carcinoma cells (Wolff et al, 2019), non-small cell lung carcinoma (Liu and Fang, 1983; Ciaramella et al, 2019) and prostate cancer cells (Masure et al, 1983). Ciaramella et al (2019) also correlated the anti-cancer activity of PPARγ to its effects on cancer microenvironment bioenergetics and metabolism.…”

Section: Potential Effect Of Pparγ Agonists On Cancersupporting

confidence: 57%

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

et al. 2019

View full text Add to dashboard Cite

Chemotherapy-induced neuropathic pain (CINP) is one of the most severe side effects of anticancer agents, such as platinum-and taxanes-derived drugs (oxaliplatin, cisplatin, carboplatin and paclitaxel). CINP may even be a factor of interruption of treatment and consequently increasing the risk of death. Besides that, it is important to take into consideration that the incidence of cancer is increasing worldwide, including colorectal, gastric, lung, cervical, ovary and breast cancers, all treated with the aforementioned drugs, justifying the concern of the medical community about the patient's quality of life. Several physiopathological mechanisms have already been described for CINP, such as changes in axonal transport, mitochondrial damage, increased ion channel activity and inflammation in the central nervous system (CNS). Another less frequent event that may occur after chemotherapy, particularly under oxaliplatin treatment, is the central neurotoxicity leading to disorders such as mental confusion, catatonia, hyporeflexia, etc. To date, no pharmacological therapy has shown satisfactory effect in these cases. In this scenario, duloxetine is the only drug currently in clinical use. Peroxisome proliferator-activated receptors (PPARs) belong to the class of nuclear receptors and are present in several tissues, mainly participating in lipid and glucose metabolism and inflammatory response. There are three PPAR isoforms: α, β/δ and γ. PPARγ, the protagonist of this review, is expressed in adipose tissue, large intestine, spleen and neutrophils. This subtype also plays important role in energy balance, lipid biosynthesis and adipogenesis. The effects of PPARγ agonists, known for their positive activity on type II diabetes mellitus, have been explored and present promising effects in the control of neuropathic pain, including CINP, and also cancer. This review focuses largely on the mechanisms involved in chemotherapy-induced neuropathy and the effects of the activation of PPARγ to treat CINP. It is the aim of this review to help understanding and developing novel CINP therapeutic strategies integrating PPARγ signalling.

show abstract

Section: Potential Effect Of Pparγ Agonists On Cancersupporting

confidence: 57%

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A meta-analysis identified an association of PPARG c.1347 C > T polymorphism with elevated risk of developing malignancies such as glioblastoma and esophageal cancer [33]. In clear cell renal cell cancer, PPARG suppresses cell migration and proliferation and induces apoptosis by inhibiting SIX homeobox 2 [34]. Sabatino et al [35] reported that ring finger domains 1 regulates PPARG negatively and is associated with higher clonogenic, proliferative and migratory potential in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma

Zhang

Zheng

Lin

et al. 2020

Aging

126

124

View full text Add to dashboard Cite

This work aimed to investigate tumor-infiltrating immune cells (TIICs) and immune-associated genes in the tumor microenvironment of osteosarcoma. An algorithm known as ESTIMATE was applied for immune score assessment, and osteosarcoma cases were assigned to the high and low immune score groups. Immuneassociated genes between these groups were compared, and an optimal immune-related risk model was built by Cox regression analyses. The deconvolution algorithm (referred to as CIBERSORT) was applied to assess 22 TIICs for their amounts in the osteosarcoma microenvironment. Osteosarcoma cases with high immune score had significantly improved outcome (P<0.01). The proportions of naive B cells and M0 macrophages were significantly lower in high immune score tissues compared with the low immune score group (P<0.05), while the amounts of M1 macrophages, M2 macrophages, and resting dendritic cells were significantly higher (P<0.05). Important immune-associated genes were determined to generate a prognostic model by Cox regression analysis. Interestingly, cases with high risk score had poor outcome (P<0.01). The areas under the curve (AUC) for the risk model in predicting 1, 3 and 5-year survival were 0.634, 0.781, and 0.809, respectively. Gene set enrichment analysis suggested immunosuppression in high-risk osteosarcoma patients, in association with poor outcome.

show abstract

“…We found that PPARG, CP2, and HEN1 participate in the development of tumors. [16][17][18] Our study has some limitations. For instance, we found an unstable result in the sensitivity analysis for the rs1610216 SNP.…”

Section: Discussionmentioning

confidence: 93%

Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk

et al. 2020

View full text Add to dashboard Cite

Objective The aim of the study was to quantitatively assess the association of metallothionein 2A ( MT2A) polymorphisms rs28366003 and rs1610216 with cancer risk. Methods Crude odd ratios (OR) with 95% confidence intervals (CI) were used to estimate associations of the polymorphisms with cancer risk. Results Six eligible case-control studies with 1899 cases and 2437 controls focused on rs28366003, and three of those six studies, with 548 cases and 926 controls, additionally focused on rs1610216. Pooled analysis showed that MT2A rs28366003 and rs1610216 were associated with cancer risk: (AG + GG) vs. AA, OR = 2.67; GG vs. (AG + AA), OR = 5.97; GG vs. AA, OR = 6.80; AG vs. AA, OR = 2.46; G vs. A, OR = 2.67 for rs28366003; and CC vs. (TC+TT), OR = 2.51; CC vs. TT, OR = 2.42 for rs1610216. Subgroup analysis based on ethnicity showed a significant association of rs28366003 with cancer risk in Asian and Caucasian populations. However, a significant association of rs1610216 with cancer risk was found only in the Asian population. Conclusion MT2A rs28366003 and rs1610216 polymorphisms were associated with cancer risk and might serve as genetic biomarkers for predicting cancer risk. However, larger studies are needed to confirm these findings.

show abstract

PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma

Cited by 14 publications

References 16 publications

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma

Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk

Contact Info

Product

Resources

About